Article
Multidisciplinary Sciences
Yusuke Orii, Eriko Kunikane, Yutaka Yamada, Masakazu Morioka, Kentaro Iwasaki, Shogo Arimura, Akemi Mizuno, Masaru Inatani
Summary: This study evaluated the concentrations of brimonidine and timolol in the vitreous and aqueous humors after instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution. The majority of patients showed a brimonidine concentration >2 nM in the vitreous humor. Brimonidine and timolol may be distributed in the ocular tissues through an identical pathway after topical instillation.
Article
Medicine, General & Internal
Jing Yang, Xiaodi Zhang, Mei Zhong, Yanhui Bai, Wentao Liu, Jinge Hu, Weiqun Wang
Summary: This study aims to investigate the differences between 0.2% and 0.15% brimonidine tartrate eye drops in terms of anti-mydriatic effects and optical quality under different light conditions. It was found that 0.15% brimonidine tartrate eye drops had similar anti-mydriatic ability to 0.2% concentration, but provided better visual quality and hardly induced pupil shift.
FRONTIERS IN MEDICINE
(2023)
Article
Medicine, General & Internal
Yusuke Orii, Eriko Kunikane, Yutaka Yamada, Masakazu Morioka, Kentaro Iwasaki, Shogo Arimura, Akemi Mizuno, Masaru Inatani
Summary: This study evaluated the concentrations of brimonidine and brinzolamide in the vitreous and aqueous humor after instillation of a 0.1% brimonidine tartrate and 1% brinzolamide fixed-combination ophthalmic suspension. The results showed that the concentration of brimonidine in the vitreous samples was greater than 2 nM, indicating its activation of α2 receptors. However, there was no significant correlation between the concentrations of brimonidine in the vitreous and aqueous humor samples, suggesting the existence of another pathway to the vitreous humor.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Nanoscience & Nanotechnology
Engy A. Abdel Azim, Seham A. Elkheshen, Rania M. Hathout, Marwa A. Fouly, Nada M. El Hoffy
Summary: The gelatinized-core liposomes successfully increased the entrapment efficiency of hydrophilic drugs, improved corneal penetration, and enhanced physical stability. The optimized formulations significantly reduced intra-ocular pressure in vivo and sustained the pharmacological effect for a longer period compared to drug solutions.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Ophthalmology
Pankaj Kumar Sharma, Meenakshi Kanwar Chauhan
Summary: The study aimed to develop BRT-PLGA-TPGS nanoparticles in a thermosensitive in situ gel for improved mucoadhesive properties and drug holding capacity in the management of glaucoma. The optimized formulation showed enhanced transcorneal permeability, sustained drug release, and greater reduction in intraocular pressure compared to marketed eye drops. Incorporating the nanoparticles into the gel matrix provided a promising approach for effective glaucoma treatment.
CURRENT EYE RESEARCH
(2021)
Article
Ophthalmology
Mitra Nejad, Shawn R. Lin, Linda H. Hwang, Mark Landig, Saba Al-Hashimi, John D. Bartlett
Summary: The study evaluated the effect of brimonidine tartrate 0.025% ophthalmic solution on pupil size under scotopic conditions in healthy adults. Significant miosis was observed post-instillation, with greater effect in light irides compared to dark irides. Further research is needed to determine the clinical significance of this effect.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2021)
Article
Pharmacology & Pharmacy
Jihei Sara Lee, Chan Yun Kim
Summary: Brimonidine tartrate is an effective and safe treatment for reducing ocular redness, providing relief for up to 8 hours without causing common side effects associated with other vasoconstrictors.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Po-Han Yeh, Yu-Chun Cheng, Shian-Sen Shie, Yung-Sung Lee, Su-Chin Shen, Henry Shen-Lih Chen, Wei-Chi Wu, Wei-Wen Su
Summary: The study found that brimonidine allergy typically occurs within 6 months of treatment initiation, with a peak at 2 to 4 months. Brimonidine allergy resulted in an increase in intraocular pressure, especially pronounced in patients receiving brimonidine monotherapy.
Article
Materials Science, Multidisciplinary
Rosalia Moreddu, Nasim Mahmoodi, Panagiotis Kassanos, Daniele Vigolo, Paula M. Mendes, Ali K. Yetisen
Summary: Intraocular pressure is a crucial physiological parameter in ocular health, but its variability can lead to measurement errors. Developing portable solutions for continuous monitoring the IOP is a critical goal in ophthalmology.
ACS APPLIED POLYMER MATERIALS
(2021)
Article
Pharmacology & Pharmacy
Yujin Zhao, Chang Huang, Zhutian Zhang, Jiaxu Hong, Jianjiang Xu, Xinghuai Sun, Jianguo Sun
Summary: A highly efficient brimonidine silicone rubber implant has been developed for sustained reduction of intraocular pressure and treatment of glaucoma. The implant shows sustained release, good biocompatibility, and effectively reduces intraocular pressure for an extended period.
Article
Materials Science, Biomaterials
Chang Huang, Yuening Shen, Yujin Zhao, Zhutian Zhang, Shunxiang Gao, Jiaxu Hong, Jianjiang Xu, Qingtao Meng, Xinghuai Sun, Jianguo Sun
Summary: Glaucoma is a major cause of irreversible blindness, with an estimated global impact on 111 million people by 2040. Intraocular pressure (IOP) is the only controllable risk factor for the disease, and current treatment options focus on reducing IOP through the use of daily eye drops. However, eye drops have limitations such as poor bioavailability and unsatisfactory therapeutic effects, leading to issues with patient compliance. This study investigates a new approach using a brimonidine-loaded silicone rubber implant coated with polydimethylsiloxane for sustained IOP reduction treatment.
REGENERATIVE BIOMATERIALS
(2023)
Article
Environmental Sciences
Thamires Martins, Claudia Schinke, Sonia C. N. Queiroz, Patricia A. de C. Braga, Fabio S. P. Silva, Itamar S. Melo, Felix G. R. Reyes
Summary: The fungus Acremonium camptosporum associated with the marine sponge Aplysina fulva was found to produce antibacterial secondary metabolites. Analysis of mass spectra data revealed the presence of cytotoxic compounds, indicating a close association between the sponge and the fungus with its compounds.
Article
Medicine, Research & Experimental
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Hiroomi Minami, Satoshi Kojima, Tomoyuki Isobe, Mizuho Kanazawa, Hideki Suganami
Summary: This study evaluated the pharmacologic effects of RBFC treatment compared to its separate components- ripasudil or brimonidine. The results showed that RBFC significantly reduced intraocular pressure and was more effective than ripasudil or brimonidine at certain time points. RBFC treatment had some side effects, such as transient conjunctival hyperemia and morphologic changes in corneal endothelial cells.
ADVANCES IN THERAPY
(2023)
Article
Multidisciplinary Sciences
Ko Eun Kim, Chang Kyu Lee, Jonghoon Shin, Yuri Kim, Seungsoo Rho
Summary: This multicenter clinical trial compared the efficacy and safety of preserved and preservative-free brimonidine tartrate 0.15% in patients with open-angle glaucoma and ocular hypertension. After 12 weeks, both groups showed similar IOP reduction and drug tolerance. The preservative-free group had better tear-film break-up time and higher patient satisfaction. Preservative-free brimonidine tartrate demonstrated comparable efficacy and safety, better corneal tear film stability, and patient satisfaction compared to preserved brimonidine.
SCIENTIFIC REPORTS
(2023)
Article
Immunology
Nazli Ecem Dal-Bekar, Agnieszka Siomek-Gorecka, Daniel Gackowski, Aydan Koken-Avsar, Handan Yarkan-Tugsal, Merih Birlik, Huray Islekel
Summary: This study provides the first absolute quantification of epigenetic DNA modification products in systemic sclerosis (SSc). The results demonstrate a global hypomethylation pattern in SSc, and also suggest a relationship between lung, gastrointestinal, and vascular involvement with epigenetic changes.
CLINICAL IMMUNOLOGY
(2022)